47
Participants
Start Date
May 6, 2019
Primary Completion Date
July 1, 2022
Study Completion Date
May 1, 2023
Saline
Placebo
Lefitolimod
A TLR9 agonist administered s.c. once weekly for 8 weeks.
3BNC117 and 10-1074
Broadly neutralizing antibodies against HIV env administered two times with a 3 week interval.
Dept. of Infectious Diseases, Rigshospitalet, Copenhagen
Dept. of Infectious Diseases, Amager and Hvidovre Hospitals, Hvidovre
Dept. of Infectious Diseases, Odense University Hospital, Odense
Dept. of Infectious Diseases, Aarhus University Hospital, Aarhus
Dept. of Infectious Diseases, Aalborg University Hospital, Aalborg
Dept. of Internal Medicine, University of Utah, Salt Lake City
Alfred Hospital and Monash University, Melbourne
Oslo University Hospital, Oslo
Aalborg University Hospital
OTHER
Odense University Hospital
OTHER
Rigshospitalet, Denmark
OTHER
Hvidovre University Hospital
OTHER
The Peter Doherty Institute for Infection and Immunity
OTHER
University of Utah
OTHER
Oslo University Hospital
OTHER
University of Aarhus
OTHER